Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer

Background: Amrubicin hydrochloride is administered as second- or third-line therapy for small cell lung cancer, and is known to cause severe myelotoxicity. This study evaluated the efficacy and safety of weekly amrubicin for refractory/relapsed small cell lung cancer.  Patients and Methods:  A sing...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:In Vivo
Main Authors: YOSHIOKA, HIROSHIGE, KOGURE, YOSHIHITO, ANDO, MASAHIKO, KITAGAWA, CHIYOE, IWASAKU, MASAHIRO, NIWA, TAKASHI, SAKA, HIDEO
Format: Artigo
Sprog:Inglês
Udgivet: International Institute of Anticancer Research 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6365753/
https://ncbi.nlm.nih.gov/pubmed/30348719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11417
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker